Skip to main content
HLB SCIENCE Inc. logo

HLB SCIENCE Inc. — Investor Relations & Filings

Ticker · 343090 ISIN · KR7343090007 KO Professional, scientific and technical activities
Open in API
Filings indexed 187 across all filing types
Latest filing 2022-12-23 Audit Report / Informat…
Country KR South Korea
Listing KO 343090

About HLB SCIENCE Inc.

https://hlbscience.com/eng/index.php

HLB SCIENCE Inc. is a biopharmaceutical company specializing in the development of innovative drugs and diagnostics for infectious and immune-related diseases. The company's primary research focuses on creating therapeutics for sepsis, superbacteria infections, and Alzheimer's disease. Its key pipeline candidate for sepsis, DD-S052P, is a novel antibiotic designed to eliminate both bacteria and their associated endotoxins to mitigate cytokine storms. For Alzheimer's disease, HLB SCIENCE is advancing DD-A279, a treatment that modulates lipopolysaccharides (LPS) and gram-negative bacteria in the central nervous system. This therapeutic effort is complemented by the development of DD-A514, a diagnostic kit for the early detection of Alzheimer's.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Dandi Bioscience Co., Ltd. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, etc.), and detailed notes to the financial statements. It also explicitly mentions corrections made to previous financial statements (1st and 2nd corrections). This fits the definition of an Audit Report (AR) as it is a standalone audit document detailing accounting principles and financial results, distinct from a full Annual Report (10-K). FY 2020
2022-12-23 Korean
[기재정정]사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) filed by a Korean company, which is the equivalent of an Annual Report (10-K). It contains detailed financial information, management discussion, business activities, and governance details for the fiscal year. Although it is a 'correction' (정정) filing, the content is a comprehensive annual report, not just a publication announcement. FY 2021
2022-12-23 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 90% confidence The document is a short regulatory notice regarding the setting of a record date for the purpose of holding an Annual General Meeting (AGM). It does not contain the full AGM materials or the meeting results, but rather serves as a formal regulatory notification of the upcoming meeting process. Given the specific nature of the notice and the lack of a better fit for 'meeting preparation notices' in the provided schema, it falls under the general regulatory filing category.
2022-12-15 Korean
기업설명회(IR)개최결과
Report Publication Announcement Classification · 100% confidence The document is a short notification (855 characters) announcing the results of an Investor Relations (IR) event held by HLB Science. It provides details such as the date, location, attendees, and the fact that IR materials were posted to the exchange's disclosure system. Since it is a brief announcement regarding the occurrence of an event and the availability of materials rather than the presentation itself, it falls under the category of a regulatory filing announcement.
2022-11-25 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and logistics of an upcoming Investor Relations (IR) event (기업설명회). It provides the date, location, target audience, and purpose of the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it is under 5,000 characters, it falls under the category of a Report Publication Announcement or general regulatory filing regarding corporate events.
2022-11-09 Korean
전환가액의조정(제2회차 CB)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price of convertible bonds (CB) for HLB Science. It details the change in conversion price, the number of convertible shares, and the rationale (market price decline). This type of disclosure regarding capital structure changes, specifically related to convertible debt instruments, falls under the 'Capital/Financing Update' category.
2022-10-24 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.